Google
PTHS — PELTHOS THERAPEUTICS INC. (Healthcare >> Biotechnology)
PTHS FAQ
What is PTHS's ROE?
PELTHOS THERAPEUTICS INC. reports a Return on Equity (ROE) of -146.97%.
What is PTHS's dividend yield?
PELTHOS THERAPEUTICS INC. offers a dividend yield of 0.00%.
What is PTHS's Deepscope Quality Score?
Deepscope rates PTHS's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PTHS?
Deepscope's AI Timing Score for PTHS is 66 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PTHS belong to?
PELTHOS THERAPEUTICS INC. is classified under the Healthcare >> Biotechnology sector on the NYSE MKT exchange.
|
USD 25.55
Price
-0.31
(-1.20%)
Day Change
|
|
|---|
PTHS, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Negative growth of ROE in the last year.
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 25.55 |
| PBV / Sector |
2.56 / 4.63
|
| Earning Per Share | -14.65 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.59 M
GREAT
|
| Average 1W Daily Value |
0.18 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:51 |
| Symbol | PTHS |
| Name | PELTHOS THERAPEUTICS INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE MKT |
| Listed Shares | 3.48 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 89.95 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 4020 Stirrup Creek Drive, Durham, NC, United States, 27703
Phone: 919 908 2400
Website: https://pelthos.com
Employees: 92
Sector: Healthcare >> Biotechnology
Description: Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
